Maternal citrulline supplementation prevents prenatal dexamethasone-induced programmed hypertension
about
Reprogramming: A Preventive Strategy in Hypertension Focusing on the KidneyPPARs Link Early Life Nutritional Insults to Later Programmed Hypertension and Metabolic SyndromeTargeting on Asymmetric Dimethylarginine-Related Nitric Oxide-Reactive Oxygen Species Imbalance to Reprogram the Development of HypertensionInterplay between Oxidative Stress and Nutrient Sensing Signaling in the Developmental Origins of Cardiovascular Disease.Neonatal Citrulline Supplementation and Later Exposure to a High Fructose Diet in Rats Born with a Low Birth Weight: A Preliminary ReportRestoration of asymmetric dimethylarginine-nitric oxide balance to prevent the development of hypertension.Transcriptional regulation of programmed hypertension by melatonin: an epigenetic perspective.Long-term effects of maternal citrulline supplementation on renal transcriptome prevention of nitric oxide depletion-related programmed hypertension: the impact of gene-nutrient interactions.Plasma levels of dimethylarginines in preterm very low birth weight neonates: its relation with perinatal factors and short-term outcome.Transcriptome analysis in rat kidneys: importance of genes involved in programmed hypertension.Programming Effects of Prenatal Glucocorticoid Exposure with a Postnatal High-Fat Diet in Diabetes Mellitus.Toxic Dimethylarginines: Asymmetric Dimethylarginine (ADMA) and Symmetric Dimethylarginine (SDMA).Thiazide-sensitive Na+-Cl- cotransporter: genetic polymorphisms and human diseases.Primary Pediatric Hypertension: Current Understanding and Emerging Concepts.Maternal citrulline supplementation prevents prenatal N(G)-nitro-L-arginine-methyl ester (L-NAME)-induced programmed hypertension in rats.
P2860
Q26771815-45E7B683-F6D0-41BC-8814-77CE737531DBQ26771825-2C4CD659-6835-4330-9A8B-DD9A6182B5BCQ28069733-5654F5A5-82A7-4097-BCB1-413E661198E5Q30234757-EF534A45-3637-44F6-9269-9C74B9E6101DQ33616820-8F8AAD3B-1396-4A0D-BA7B-B95D4626EA7AQ34072296-B9D61CB0-2241-4C97-8A67-7065544C3FECQ34486865-DAAB1E84-ADD3-404F-815B-5E2977A6CCDAQ34835432-A67F8362-D4E6-4C14-930C-72E6E429FA83Q35016382-B7C7B624-4063-40CE-A550-DB5B8EB2EB45Q35380509-AD18CE40-F50D-4FA1-8B72-CAA42571F332Q36847131-629806FD-1FE4-4141-87A3-860EAA373984Q37727924-64EC573A-D6EE-42EB-9683-62B5B1D743F0Q38405178-5395C80F-4D91-4184-90C1-819E2CDBA710Q40105112-25B16D7F-51C4-42C5-80F0-AF8581E0D586Q43716185-99211FB7-28AF-4C2B-BC6C-C3FF95ECC84C
P2860
Maternal citrulline supplementation prevents prenatal dexamethasone-induced programmed hypertension
description
im März 2014 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована в березні 2014
@uk
name
Maternal citrulline supplement ...... nduced programmed hypertension
@en
Maternal citrulline supplement ...... nduced programmed hypertension
@nl
type
label
Maternal citrulline supplement ...... nduced programmed hypertension
@en
Maternal citrulline supplement ...... nduced programmed hypertension
@nl
prefLabel
Maternal citrulline supplement ...... nduced programmed hypertension
@en
Maternal citrulline supplement ...... nduced programmed hypertension
@nl
P2093
P2860
P1476
Maternal citrulline supplement ...... nduced programmed hypertension
@en
P2093
C. C. Chen
J. M. Sheen
L. T. Huang
M. M. Tiao
Y. L. Tain
P2860
P304
P356
10.3109/10715762.2014.895341
P577
2014-03-17T00:00:00Z